Literature DB >> 10777239

The natural history of claudication: risk to life and limb.

J Dormandy1, L Heeck, S Vig.   

Abstract

Although a patient with intermittent claudication (IC) will fear progression to severe disease and amputation, this is a relatively rare outcome of claudication, with only 1% to 3% of claudicants ever requiring major amputation over a 5-year period. Indeed, in one study, 50% of claudicants became symptom free during 5 years' follow-up. All the new evidence over the last 40 years has not altered the impression that only about one fourth of patients with IC will ever significantly deteriorate, and that deterioration is most frequent during the first year after diagnosis (6 to 9%) compared with 2% to 3% per annum thereafter. Smoking is the most important risk factor for the progression of local disease in the legs, with an amputation rate 11 times greater in smokers than nonsmokers. Diabetes, male gender, and hypertension are also important risk factors for progression. Because cerebrovascular disease (CVD), coronary artery disease (CAD), and peripheral arterial occlusive disease (PAOD) coexist, PAOD and IC should be regarded as a marker for increased risk from fatal and nonfatal cardiovascular event, and 2% to 4% of claudicants have a nonfatal cardiovascular event every year. The risk is higher in the first year after developing IC than in a long-standing stable claudicant, and the average claudicant is more likely to have a nonfatal myocardial infarction (MI) or stroke in the next year that of ever requiring a major amputation for his leg ischemia. The mortality in claudicants is 30% at 5 years, 50% at 10 years, and 70% at 15 years, without any clear decrease in these figures over the last 30 to 40 years. The mortality of claudicants is approximately two and a half times that of an age-matched general population.

Entities:  

Mesh:

Year:  1999        PMID: 10777239

Source DB:  PubMed          Journal:  Semin Vasc Surg        ISSN: 0895-7967            Impact factor:   1.000


  31 in total

Review 1.  Pharmacological treatment of patients with peripheral arterial disease.

Authors:  Chin K Kim; Carsten M Schmalfuss; Richard S Schofield; David S Sheps
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Management of peripheral arterial disease in primary care.

Authors:  Paul Burns; Stephen Gough; Andrew W Bradbury
Journal:  BMJ       Date:  2003-03-15

Review 3.  Multislice computed tomography angiography in the diagnosis of cardiovascular disease: 3D visualizations.

Authors:  Zhonghua Sun
Journal:  Front Med       Date:  2011-10-02       Impact factor: 4.592

Review 4.  [Rational minimally invasive treatment of pAOD: when should a conservative approach, PTA, or stent be chosen?].

Authors:  S Müller-Hülsbeck
Journal:  Radiologe       Date:  2006-11       Impact factor: 0.635

Review 5.  Whole-Body MRA.

Authors:  Harald Kramer; Harald H Quick; Bernd Tombach; Stefan O Schoenberg; Joerg Barkhausen
Journal:  Eur Radiol       Date:  2008-05-20       Impact factor: 5.315

6.  APC resistance due to Factor V Leiden is not related to baseline inflammatory mediators or survival up to 10 years in patients with critical limb ischemia.

Authors:  Ellis S Sampram; Anders Gottsäter; Bengt Lindblad; Peter J Svensson
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

7.  Prevalence of peripheral arterial disease - results of the Heinz Nixdorf recall study.

Authors:  Knut Kröger; Andreas Stang; Jana Kondratieva; Susanne Moebus; Eva Beck; Axel Schmermund; Stefan Möhlenkamp; Nico Dragano; Johannes Siegrist; Karl-Heinz Jöckel; Raimund Erbel
Journal:  Eur J Epidemiol       Date:  2006       Impact factor: 8.082

8.  The effect of claudication pain on temporal and spatial gait measures during self-paced ambulation.

Authors:  Andrew W Gardner; Polly S Montgomery; Raphael M Ritti-Dias; Larry Forrester
Journal:  Vasc Med       Date:  2009-09-25       Impact factor: 3.239

Review 9.  Medical Therapy in Peripheral Artery Disease and Critical Limb Ischemia.

Authors:  T Raymond Foley; Stephen W Waldo; Ehrin J Armstrong
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-07

10.  Resting energy expenditure in subjects with and without intermittent claudication.

Authors:  Andrew W Gardner; Polly S Montgomery
Journal:  Metabolism       Date:  2009-07       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.